Samuel Funt, MD
Memorial Sloan Kettering Cancer Center
6
6
3
N/A
0
10
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+2 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Andrea B Apolo, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Anissa MEGZARI
Centre Hospitalier Universitaire de NÄ«mes
Shared therapeutic areas:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Charles L. Loprinzi, MD
Mayo Clinic
Shared therapeutic areas:
Deborah E Citrin, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Shakeel Modak, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Xiaoli Lan, PhD
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
All 6 trials loaded